04.07.2008 - Apria Healthcare Names New President of Coram
Apria Healthcare Group Inc. (NYSE:AHG) today announced the appointment of Daniel E. Greenleaf to lead its Coram Specialty Infusion Services division as President, replacing John Arlotta, who, as previously announced during Apria's December 2007 acquisition of Coram, Inc., is scheduled to depart the organization in June 2008. Mr. Greenleaf will be based in the Coram division office located in Denver, Colorado.

Mr. Greenleaf most recently served as President and Chief Executive Officer of VioQuest Pharmaceuticals, Inc., a New Jersey-based biopharmaceutical company focused on the acquisition, development and commercialization of oncology drug therapies, from 2005 to 2007.

12.03.2007 - Apria Healthcare Completes Purchase of Coram, Inc.
Apria Healthcare Group Inc. (“Apria Healthcare” or “Apria”) (NYSE:AHG) today announced that it has completed its acquisition of Coram, Inc. (“Coram”) for a cash purchase price of $350 million. Coram provides a comprehensive range of home infusion therapies and specialty pharmaceuticals to 65,000 patients through a network of more than 70 home infusion branches across the country, 50 company-owned and operated ambulatory infusion suites and 2,100 employees.

“We are excited about the opportunities associated with the Coram acquisition,” said Lawrence M. Higby, Apria’s Chief Executive Officer. “Strategically, it transforms the company by diversifying our product and payor mix and positioning us favorably in the rapidly growing specialty pharmaceutical and infusion markets. From a customer perspective, we believe it offers a number of expanded clinical and integrated homecare solutions to patients, physicians and payors alike. Now that the transaction is complete, we will begin implementing our integration plans, and look forward to realizing the strategic and financial synergies that this transaction creates for Apria in 2008 and beyond.”

10.15.2007 - Apria Healthcare Signs Definitive Agreement to Acquire Coram, Inc.

7.24.2007 - Coram Now Providing Soliris™ Infusions
Coram has announced that it has become an approved provider of Soliris™ for Alexion Pharmaceuticals, Inc. Soliris is the first and only therapy approved for paroxysmal nocturnal hemoglobinuria, or PNH, a rare, disabling and life-threatening blood disorder characterized by chronic red blood cell destruction, otherwise known as hemolysis.

5.09.2007 - CoramRx™ Specialty Pharmacy Services
Receives ACHC Accreditation
Coram, Inc. announces that its specialty pharmacy unit, CoramRx, has been granted accreditation by the Accreditation Commission for Health Care, Inc. (ACHC). Complementing Coram's specialty infusion services, CoramRx provides drug delivery and clinical management services for injectable, infused and oral medications to patients and physician offices nationwide, supporting both Major Medical and Pharmacy benefit programs.

9.18.2006 - Coram, Inc. and MedAvant™ Healthcare Solutions Expand National Relationship to Include Pharmacy Services for NPPN
Coram announced that it has expanded its agreement with MedAvant Healthcare Solutions to include specialty pharmacy services for MedAvant's National Preferred Provider Network (NPPN), one of the largest national preferred provider organizations in the country.

8.23.2006 - Coram, Inc. Infusion Suites Now Providing Tysabri® Infusions
Coram announced that it has been approved to provide Tysabri (natalizumab), the monotherapy treatment for relapsing forms of multiple sclerosis (MS). Coram treated its first Tysabri patient at its Boise, Idaho branch on August 14, 2006. Currently, Tysabri is offered at select Coram Infusion Suites throughout the country; it is anticipated the treatment will be available through all Coram suites by the end of September, 2006.

7.31.2006 - Coram, Inc. Endorses H.R. 5791
Coram announced its support and endorsement of H.R. 5791, The Medicare Home Infusion Therapy Consolidated Coverage Act of 2006. This bi-partisan bill states that Medicare will cover home infusion therapy under Medicare Part B, including all of the drugs, supplies, equipment and professional pharmacy and nursing services necessary to provide safe and effective treatment.

6.01.2006 - Coram, Inc. Named Distributor of Vivitrol™
Coram announced today that it has been selected by Alkermes, Inc., (Nasdaq: ALKS) and Cephalon, Inc., (Nasdaq: CEPH) to be a national provider of Vivitrol™, the first once-monthly injectable medication for the treatment of alcohol dependence.

4.27.2006 - Coram, Inc. Moves to Focus Efforts on Core Therapies
In a move to further focus the company's efforts on its core business and expand its specialty pharmacy offerings, Coram, Inc. announced today that it has sold the assets of two of its respiratory therapy locations in Lenexa, KS and Plymouth, MI to Lincare, Inc., a provider of in-home respiratory care, infusion therapy and medical equipment.

4.12.2006 - Coram, Inc. to Provide Vivaglobin®, New Subcutaneous Immunoglobulin
Coram, Inc. announced today that it has been selected by ZLB Behring as a national provider of Vivaglobin® (Immune Globulin Subcutaneous [Human]). Vivaglobin® recently became the first and only U.S. Food and Drug Administration-approved subcutaneous (SC) immunoglobulin (lg) treatment and can be safely self-administered by primary immunodeficiency (PI) patients under a physician's care in the United States.

> News Archive

To learn more about Coram, contact us. To enroll or refer a patient to Coram, click here.